open access

Vol 29, No 1 (2022)
Research Letter
Submitted: 2021-07-31
Accepted: 2021-10-24
Published online: 2021-11-15
Get Citation

Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization

Jaroslaw Meyer-Szary, Magdalena Bazgier1, Paulina Lubocka1, Karolina Dorniak2, Robert Sabiniewicz1
DOI: 10.5603/CJ.a2021.0152
·
Pubmed: 34787887
·
Cardiol J 2022;29(1):160-162.
Affiliations
  1. Department of Pediatric Cardiology and Congenital Hear t Diseases, Faculty of Medicine, Medical University of Gdansk, Poland
  2. Department of Cardiac Diagnostics, Faculty of Medicine, Medical University of Gdansk, Poland

open access

Vol 29, No 1 (2022)
Research letters — COVID-19
Submitted: 2021-07-31
Accepted: 2021-10-24
Published online: 2021-11-15

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization

Journal

Cardiology Journal

Issue

Vol 29, No 1 (2022)

Article type

Research Letter

Pages

160-162

Published online

2021-11-15

Page views

26095

Article views/downloads

3806

DOI

10.5603/CJ.a2021.0152

Pubmed

34787887

Bibliographic record

Cardiol J 2022;29(1):160-162.

Authors

Jaroslaw Meyer-Szary
Magdalena Bazgier
Paulina Lubocka
Karolina Dorniak
Robert Sabiniewicz

References (10)
  1. Habib MB, Hamamyh T, Elyas A, et al. Acute myocarditis following administration of BNT162b2 vaccine. IDCases. 2021; 25: e01197.
  2. Deb A, Abdelmalek J, Iwuji K, et al. Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database. J Prim Care Community Health. 2021; 12: 21501327211029230.
  3. Watkins K, Griffin G, Septaric K, et al. Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med. 2021 [Epub ahead of print].
  4. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5): 403–416.
  5. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
  6. Maron B, Udelson J, Bonow R, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. Circulation. 2015; 132(22).
  7. Muthukumar A, Narasimhan M, Li QZ, et al. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. Circulation. 2021; 144(6): 487–498.
  8. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-Based COVID-19 vaccines. JAMA Cardiol. 2021; 6(10): 1115–1117.
  9. Bajaj R, Sinclair H, Patel K, et al. Delayed-onset myocarditis following COVID-19. Lancet Resp Med. 2021; 9(4): e32–e34.
  10. Pfizer-BioNTech. Vaccines and Related Biological Products Advisory Committee Meeting FDA Briefing Document Pfizer- -BioNTech COVID-19 Vaccine Sponsor: Pfizer and BioNTech. U.S. Food and Drug Administration. https://www.fda.gov/media/144245/download ((Accessed 31.07.2021)).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl